Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Surufatinib in Hepatic Impairment
NCT04755075Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of surufatinib in neuroendocrine tumors (NETs) (3 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity and 1 more. Started Feb 2021; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04755075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04755075.